Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma

In osteosarcoma, patient survival has not changed in over 30 years. Multiple phase II trials have been conducted in osteosarcoma using the Response Evaluation Criteria in Solid Tumors (RECIST) as a primary endpoint; however, none of these have revealed new treatment strategies. We investigated RECIST in newly diagnosed patients who received neoadjuvant chemotherapy proven to be beneficial.

[1]  Response Evaluation Criteria in Solid Tumors , 2020, Definitions.

[2]  D. Hawkins,et al.  Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Adamson,et al.  Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study , 2013, Pediatric blood & cancer.

[4]  Paul A Meyers,et al.  Outcome for adolescent and young adult patients with osteosarcoma , 2012, Cancer.

[5]  J. Wathen,et al.  Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. , 2012, The oncologist.

[6]  P. Adamson,et al.  A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study , 2010, Pediatric blood & cancer.

[7]  K. Janeway,et al.  Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. , 2010, The Lancet. Oncology.

[8]  P. Adamson,et al.  Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group , 2010, Clinical Cancer Research.

[9]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[10]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[11]  S. Ferrari,et al.  Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. , 2005, European journal of cancer.

[12]  E. Kleinerman,et al.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[14]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[15]  M. Link,et al.  Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[17]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[18]  J. Hermans,et al.  Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy? , 1995, Clinical radiology.

[19]  D. Vanel,et al.  Osteosarcoma: chemotherapy-induced changes at MR imaging. , 1992, Radiology.

[20]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[21]  R. Gelber,et al.  Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Rosen,et al.  Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.

[23]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[24]  N. Jaffe,et al.  Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. , 2006, Journal of pediatric surgery.

[25]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Huvos,et al.  Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G Rosen,et al.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Varini,et al.  High-dose ifosfamide in advanced osteosarcoma. , 1985, Cancer treatment reports.